Discover
SYRE
Spyre Therapeutics, Inc.
100.88
1 x 100.66
1 x 100.83
bid
ask
-
4.45
4.22%
12:37 PM
timesize
| Ytd | 207.94% | |
| 1y | 561.51% |
99.84
day range
105.33
14.51
52 week range
108.14
| Open | 105.33 | Prev Close | 105.33 | Low | 99.84 | High | 105.33 | Mkt Cap | 8.75B |
| Vol | 456.10K | Avg Vol | 1.29M | EPS | -1.95 | P/E | -51.66 | Forward P/E | -31.95 |
| Beta | 3.03 | Short Ratio | 6.57 | Inst. Own | 94.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 91.24 | 200-d Avg | 54.80 | 1yr Est | 120.07 |
| Income Statement | |||
| Operating Expenses | 41.64M | ||
| Research and Development Expense | 65.50M | ||
| Selling, General and Administrative Expense | 16.14M | ||
| Operating Income | -41.64M | ||
| Net Income | -36.20M | ||
| Net Income Common Stock | -36.20M | ||
| Net Income Common Stock (USD) | -36.20M | ||
| Consolidated Income | -36.20M | ||
| Earnings per Basic Share | -0.36 | ||
| Earnings per Basic Share (USD) | -0.36 | ||
| Earnings per Diluted Share | -0.36 | ||
| Earning Before Interest & Taxes (EBIT) | -36.20M | ||
| Earning Before Interest & Taxes (USD) | -36.20M | ||
| Weighted Average Shares | 84.73M | ||
| Weighted Average Shares Diluted | 84.73M | ||
| Balance Sheet | |||
| Cash and Equivalents | 162.01M | ||
| Cash and Equivalents (USD) | 162.01M | ||
| Investments | 983.34M | ||
| Investments Current | 983.34M | ||
| Current Assets | 1.17B | ||
| Total Assets | 1.17B | ||
| Current Liabilities | 63.30M | ||
| Total Liabilities | 71.86M | ||
| Accumulated Retained Earnings (Deficit) | -1.23B | ||
| Accumulated Other Comprehensive Income | -2.40M | ||
| Shareholders Equity | 1.10B | ||
| Shareholders Equity (USD) | 1.10B | ||
| Liabilities Non-Current | 8.56M | ||
| Trade and Non-Trade Payables | 5.77M | ||
| Cash Flow | |||
| Net Cash Flow from Financing | 432.60M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 64.82M | ||
| Net Cash Flow - Business Acquisitions and Disposals | 40.00M | ||
| Issuance (Purchase) of Equity Shares | 455.82M | ||
| Net Cash Flow from Investing | -297.90M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -337.90M | ||
| Net Cash Flow from Operations | -69.88M | ||
| Share Based Compensation | 13.51M | ||